Sharon Worcester is an award-winning medical journalist for MDedge News. She has been with the company since 1996, first as the Southeast Bureau Chief (1996-2009) when the company was known as International Medical News Group, then as a freelance writer (2010-2015) before returning as a reporter in 2015. She previously worked as a daily newspaper reporter covering health and local government. Sharon currently reports primarily on oncology and hematology. She has a BA from Eckerd College and an MA in Mass Communication/Print Journalism from the University of Florida. Connect with her via LinkedIn and follow her on twitter @SW_MedReporter.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Spiera_Robert_NY_web.jpg)
ACR CRISS: A way forward for scleroderma treatment trials?
- Author:
- Sharon Worcester
CHICAGO – Recent data validate and support use of the ACR CRISS as an outcome measure in scleroderma treatment...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/November-2018/136546_Brose_Marcia_web.jpg)
Lenvatinib/Pembrolizumab shows promise in previously treated metastatic NSCLC
- Author:
- Sharon Worcester
WASHINGTON – Interim findings from a phase 1b/2 study indicate the combination shows promising clinical activity and...
News
TMB measured by NGS may ID SCLC patients who will benefit from immunotherapy
- Author:
- Sharon Worcester
WASHINGTON – Targeted next-generation sequencing may help identify SCLC patients likely to benefit from...
News
Monalizumab-cetuximab combo shows promise in advanced head and neck SCC
- Author:
- Sharon Worcester
WASHINGTON – Combined monalizumab + cetuximab is safe and promotes deep, durable responses in recurrent or...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/November-2018/Zack_Debra_web.jpg)
Development of reversible B-cell inhibitor XmAb5871 for SLE moves forward
- Author:
- Sharon Worcester
CHICAGO – The reversible B-cell inhibitor XmAb5871 shows promise for extending steroid benefits in SLE patients...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/FDA_icon3_web.jpg)
FDA expands approval of brentuximab vedotin to PTCL
- Author:
- Sharon Worcester
This is the first FDA approval of a treatment for newly-diagnosed PTCL.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/September-2018/Blum_Kristie_GA_web.jpg)
Relapsed MCL: Options for treatment
- Author:
- Sharon Worcester
There are a number of treatment options for relapsed MCL, but BTK inhibitors are particularly useful.
News
![](https://qa00.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
Early phase 2 data: Mocetinostat/durvalumab combo shows promise in mNSCLC
- Author:
- Sharon Worcester
WASHINGTON, D.C. – Mocetinostat/durvalumab shows activity and manageable AEs in metastatic NSCLC after progression...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/October-2018/135893_Sullivan_Keith_web.jpg)
Scleroderma SCOT trial findings hold similar in lung disease
- Author:
- Sharon Worcester
CHICAGO – Lung CT score changes for scleroderma-related interstitial lung disease validate hematopoietic stem...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/November-2018/Barr_Paul_M_NY_web.jpg)
Consider treatment, testing when CLL symptoms emerge
- Author:
- Sharon Worcester
CHICAGO – Predictive tests should be conducted before beginning therapy.
News
CLL: The initial work-up
- Author:
- Sharon Worcester
CHICAGO – Molecular testing has prognostic value, but still doesn’t drive treatment under updated iwCLL guidelines.
News
Prognostic features could improve ALL outcomes
- Author:
- Sharon Worcester
CHICAGO – Cytogenetic factors, minimal residual disease activity, and Philadelphia chromosome–like signature are among the features with...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/November-2018/Powell_Steven_SD_web.jpg)
Adding pembrolizumab to cisplatin-based CRT shows promise in HPV+ head and neck cancers
- Author:
- Sharon Worcester
Pembrolizumab plus cisplatin-based chemoradiotherapy shows promise for locally advanced, HPV-positive head and neck squamous cell carcinoma.
News
Refractory immune-mediated colitis: Fecal transplant may be the answer
- Author:
- Sharon Worcester
WASHINGTON – FMT shows promise for the treatment of refractory immune checkpoint inhibitor–associated colitis.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/November-2018/Hitraya_Elena_CA_web.jpg)
MBDA score predicts, tracks RA patients’ responses to tofacitinib and rituximab
- Author:
- Sharon Worcester
CHICAGO – Multibiomarker disease activity score predicts RA patients’ responses to tofacitinib and tracks rituximab responses.